Y. Karabulut Et Al. , "Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment," RHEUMATOLOGY INTERNATIONAL , vol.42, no.1, pp.81-86, 2022
Karabulut, Y. Et Al. 2022. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment. RHEUMATOLOGY INTERNATIONAL , vol.42, no.1 , 81-86.
Karabulut, Y., Gezer, H. H., & DURUÖZ, M. T., (2022). Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment. RHEUMATOLOGY INTERNATIONAL , vol.42, no.1, 81-86.
Karabulut, Yusuf, HALİSE HANDE GEZER, And MEHMET TUNCAY DURUÖZ. "Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment," RHEUMATOLOGY INTERNATIONAL , vol.42, no.1, 81-86, 2022
Karabulut, Yusuf Et Al. "Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment." RHEUMATOLOGY INTERNATIONAL , vol.42, no.1, pp.81-86, 2022
Karabulut, Y. Gezer, H. H. And DURUÖZ, M. T. (2022) . "Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment." RHEUMATOLOGY INTERNATIONAL , vol.42, no.1, pp.81-86.
@article{article, author={Yusuf Karabulut Et Al. }, title={Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment}, journal={RHEUMATOLOGY INTERNATIONAL}, year=2022, pages={81-86} }